QMS Medical Allied Services Limited — Investor Meet, 26-11-2024: Analysts/Institutional Investor Meet/Con. Call Updates

1. Financial Performance: QMS Medical Allied Services reported an operating revenue of ₹37.2 crore for Q2 FY25, up from ₹24.4 crore in Q1 FY25, reflecting a robust quarterly growth. EBITDA increased by 52.9% to ₹7.57 crore, while net profit rose 76.3% to ₹4.23 crore, yielding EBITDA and PAT margins of 20.3% and 11.3%, respectively. Year-over-year, operating income improved 30%, and EBITDA grew 51%, indicating strong operational leverage.

2. Future Outlook and Growth Drivers: Management highlighted ongoing focus on high-margin solution-based outreach, which is expected to continue driving growth. The recently acquired 51% stake in Saarathi Healthcare is anticipated to further enhance growth through integration synergies. Expansion into the hospital supplies segment is also seen as a key growth driver.

3. Order Book and Operational Updates: The company has been actively consolidating operations post-Saarathi acquisition, which contributed approximately ₹5 crore in revenue and ₹1.75 crore in net profit this quarter. The management is optimistic about increasing the number of preventive camps, targeting a 35% growth based on last year's performance.

4. Analyst Q&A Insights (Detailed):

- **Revenue and Profitability**: Clarified that Saarathi's contributions are pivotal for revenue targets.

- **Market Position and Competitive Landscape**: The management reassured investors about maintaining a competitive edge through innovative solutions tailored to client needs.

- **Operational Challenges or Risks**: Addressed current integration challenges post-acquisition, emphasizing organizational capability to manage these transitions smoothly.

- **Capex and Capital Allocation**: Plans to allocate capital towards expanding hospital supplies and workforce enhancements were discussed.

- **Strategic Priorities and Long-Term Vision**: Growth in the services segment is a central focus, with aspirations to double the combined business volume over the next three years.

5. Market or Regulatory Updates: The management reported positive sentiment from government policies favoring healthcare investments, further enhancing operational visibility.

6. Strategic Focus Areas: The company is advancing a two-vertical model—products and services—emphasizing innovation and customer service as critical themes.

7. Investor Insight: The company's robust revenue growth, strong margins, and strategic initiatives suggest a positive outlook. Given the momentum in performance and management's proactive approach to growth drivers, there appears to be merit in considering a ‘buy’ stance, while remaining watchful of integration risks related to recent acquisitions.